Prognosis studies including our own 1,2 have documented signi®cant improvement in survival of patients with SLE in more recent decades. Whereas the ®rst large series to study mortality in this disease in 1955 3 showed a survival of less than 50% at 5 y, we have shown the overall 5, 10, 15, and 20 y survival rates of 665 SLE patients followed in our observational cohort study over 24 y to be 93, 85, 79 and 68% respectively. 4 Furthermore we have shown that this improved survival was greater than the improvement in the general population in our province as the standardized mortality ratios decreased in the three time periods 1970±1977; 1978± 1985; and 1986±1994 from 10.1 to 4.8 to 3.3 respectively. 5 During this period, prognosis studies 2,5 ± 7 have demonstrated distinctive mortality patterns in these patients. Patients dying early often succumbed to active lupus and infection while patients dying after 5 y of disease often succumbed to atherosclerotic complications, although exceptions occurred in each epoch of the disease. Of interest, we have demonstrated that infection remains a major manifestation associated with mortality throughout all stages of the disease. Thus patients with SLE live longer and their disease manifestations may vary depending on the stage of the disease.
An important contribution to the understanding of the clinical presentation of SLE in the past decade has therefore been the description of the late stage mortality and morbidity features in this condition apparently unrelated to the immunologic in¯ammatory mechanisms. This evolving spectrum of clinical presentation has included accelerated atherosclerosis, dementia presenting as cognitive dysfunction, bone disease including osteoporosis and avascular necrosis, impaired quality of life on the basis of ®bromyalgia or chronic fatigue, chronic renal insuf®ciency and its sequelae and shrinking lung syndrome. Each of these manifestations is perhaps related to previous immune in¯ammatory mechanisms, or to previous or current medications. The various presentations mimic the presentations of the acute immune in¯ammatory mechanisms and clearly must be differentiated from them clinically. The careful description of some of these evolved disease states such as osteoporosis and early dementia may give insights into the mechanisms of these conditions not only in SLE patients, but also in patients without previous connective tissue diseases.
The phenomenon of death late in the course of SLE associated with coronary artery disease (CAD) was ®rst described by us in 1974 6 and con®rmed in a subsequent study. 7 The prevalence of clinically diagnosed myocardial infarction, angina, and peripheral vascular disease in the Toronto lupus cohort is 12%, comparable to the prevalence of myocardial infarction and angina reported in the Pittsburgh (6.7%) 8 and Baltimore (8.3%) 9 cohorts. Of the 124 patients who died from 1970±1993 in our clinic, 40 had post mortem examinations and 21 (40%) had evidence of moderate to severe atherosclerosis at the time of death either as a coexistent ®nding or as a primary cause of death. 2 Epidemiological studies have also con®rmed this increase in CAD. In 1993±94 the annual incidence of myocardial infarction in Canadian women was estimated at 0.001. 10 This compares to incidence rates for women in our lupus cohort of 0.005 (unpublished observations). Therefore, in women with SLE, there is a ®vefold increase in the incidence of myocardial infarction. The median age of myocardial infarction in Canadian women is 65±74 y compared to 49 y in our lupus cohort. Manzi also found that women with SLE aged 35±44 y old are 52.4 times more likely to have a myocardial infarction than controls. 8 Again two thirds of the events occurred before the age of 55 y.
We then turned our attention to detecting subclinical atherosclerotic disease which would afford clinicians a better opportunity for intervention and thereby prevention of this outcome. To do this we employed a dual isotope myocardial perfusion technique utilizing the two isotopes thallium and sestamibi. This technique has special relevance for females as it is described as giving reliable results in women as opposed to other scanning techniques. These studies have revealed in over 100 women with SLE that 40% of all of these women have abnormal myocardial perfusion, and 33% of totally asymptomatic women have these abnormalities. Preliminary results of these isotope studies have been reported. 11 This con®rmed the fact that atherosclerotic disease was prevalent and present in sub-clinical form for some years prior to manifesting as a clinical outcome.
Despite this accumulating knowledge of the role of atherosclerosis in morbidity and mortality, the importance of treating risk factors is not yet entrenched in the rheumatologist's approach to patients with SLE.
In a recent quality improvement study, we showed that rheumatologists performed well when optimzing control of lupus, managing hypertension, and minimizing steroid dose. However, they did not perform well in treating hypercholesterolemia, hyperglycemia, obesity or smoking. 12 Thus there is still a signi®cant role for educating physicians caring for patients with SLE regarding the importance of risk factors for CAD.
Finally, when patients with SLE and CAD were compared with a cohort of patients with accelerated CAD without connective tissue diseases, it was found that the SLE patients generally have one less risk factor than non SLE patients. 13 This suggests that SLE itself may be a risk factor for accelerated atherosclerosis similar to diabetes mellitus. This has also been suggested by Esdaile. 14 Neuropsychiatric manifestations are common in patients with SLE. 15 However, some patients with SLE later in their disease complain of various cognitive dysfunctions such as memory de®cits, dif®culty with calculations, spoken and written languages, poor concentration and decreased performance in the absence of any evidence of active lupus. The mechanism of this dysfunction is not understood, but may be due to previous active neurologic disease, clinical or subclinical, previous or current psychiatric disorders, or medications especially corticosteroids, previous or current. Neuropsychological testing is being increasingly used in assessing patients to detect abnormalities in those without overt cerebral disease. Therefore we used a battery of standardized neuropsychological tests to evaluate neurocognitive function in 58 patients with inactive SLE and compared them with 47 controls. All patients had a SLEDAI of 0 to minimize the possibility of subclinical disease activity. Our study showed that 43% of patients with inactive SLE had evidence of neurocognitive dysfunction compared to 19% of controls. There was no correlation between the neurocognitive dysfunction and psychiatric illness, or abnormal neurophysiologic studies (brain scan, EEG) or previous major organ involvement of SLE, atherosclerotic complications, or steroid therapy. 16 Thus neurocognitive dysfunction is an important late stage feature in inactive SLE, but its mechanism remains to be elucidated.
As patients with SLE live longer, it is anticipated that they will demonstrate the usual effects of ageing, including postmenopausal osteoporosis. In addition, corticosteroid use has long been considered a risk factor for osteoporosis, making the presence of postmenopausal osteoporosis more prevalent than in the general population. The effect of corticosteroid therapy may also be predisposing the premenopausal lupus patient to osteoporosis. In a study of 74 premenopausal female lupus patients from Barcelona bone mineral density was assessed by dual energy Xray absorptiometry in comparison to 50 control volunteers. Bone mineral density was lower in the patients compared to controls, but it was not related to prednisone dose at the time of the study, nor to cumulative prednisone doses. 17 We have also demonstrated that osteopenia andaor osteoporosis occurs commonly in premenopausal females with SLE. No demographic or clinical features of the disease were associated with the low bone mineral densities. 18 These studies suggest that patients with SLE should be treated prophylactically for this premature bone loss.
Avascular necrosis (osteonecrosis) occurs in 10± 30% of patients with SLE. 19 ± 21 Patients with osteonecrosis are generally in the younger age group and have an interval between diagnosis of lupus and osteonecrosis of about 4 y. The hip is the most commonly involved joint, although most joints in the body have been reported to have been affected. One-half to two-thirds of patients with osteonecrosis will have multiple sites and typically will have been on high-dose corticosteroids at some time during the course of their illness. There is no general agreement as to the predictive role of any speci®c manifestation of SLE, such as Raynaud's phenomenon or vasculitis in the subsequent development of osteonecrosis. 19, 20 A role for anticardiolipin has been suggested but not uniformly proven. 19 ± 21 There is currently no general consensus on pathogenesis. The diagnosis of avascular necrosis can be facilitated with the use of more advanced imaging techniques such as MRI. 22, 23 Avascular necrosis of the hip has often led to hip replacement in these patients and thus contributes to their disability.
Fatigue is among the most commonly reported symptoms in SLE, occurring in up to 80±100% of patients. 24, 25 Although fatigue is included in some disease activity measures, 26 we recently demonstrated that fatigue in patients with SLE does not correlate with disease activity. 27 Fibromyalgia has been found to be common among patients with SLE, and has recently been reported to account for many of the symptoms as well as disability in patients with SLE. 28, 29 A recent study demonstrated that ®bromyalgia is a major contributor to quality of life in patients with SLE. 29 Indeed, fatigue correlated with ®bromyalgia, depression, and lower overall health status in this population. 30 Fatigue is thus a manifestation of these conditions which are commonly co-expressed in SLE, and may re¯ect a decreased overall coping ability in these patients, rather than active disease itself.
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Thus the spectrum of clinical presentation in SLE has evolved considerably to include a number of features not explained by the acute immunologic pathogenic mechanisms considered integral to this disease. These features may mimic the presentations of classic acute lupus and thus must be carefully differentiated from them. Only with such careful segregation and description of these features will we better understand their natural history and pathogenic mechanism(s).
